Dylan Daniel, Ph.D. joins Molecular Imaging, Inc. as Director of Scientific Development

April 13, 2016

Dr. Daniel is an immunologist and preclinical oncology pharmacologist with leadership experience in all phases of early R&D for oncology and cancer immunotherapy. Dr. Daniel has a Ph.D. in Microbiology and Immunology and conducted post-doctoral work with Doug Hanahan at UCSF where he worked on immuno-oncology in genetically engineered mouse models. From there, Dr. Daniel worked at Genentech and then Novartis. In both companies he was focused on oncology pharmacology with small molecule and biologic drug discovery and development. Just previous to joining MII, Dr. Daniel was Chief Science Officer and Co-Founder of Patronus Therapeutics, Inc., a small biotechnology start-up developing novel oncology therapeutics.

Molecular Imaging, Inc. is a leading provider of preclinical oncology service to pharmaceutical and biotechnology companies.  MII uses a broad range of human and syngeneic tumor models and applies advanced pharmacology services, including flow cytometry, multi-modality imaging and focal radiation to interrogate drugs and biologics.

Dr. Daniel will interface directly with clients and potential clients to assure the optimum translation of needs into MII studies.  His experience on the industry-side and his exceptional scientific bona fides in in vivo pharmacology, oncology models, and immuno-oncology make Dr. Daniel a great resource for collaborative service development with Molecular Imaging, Inc.